Days after finally getting the FDA's go-ahead to resume the stop-and-start development of its lead candidate, Geron has signed a deal to cut Johnson & Johnson in on the process, putting the biotech in line for as much as $935 million if all goes according to plan.
Xerox, best known for its copy machines and document management systems, is investing in HealthSpot, a telemedicine provider that sets up kiosks that connect patients with physicians.
Whatever Cambridge, MA-based Millennium learned over the past two years it's been collaborating with Presage Biosciences, the experience must have been rewarding.
Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.
As chronic liver disease numbers continue to skyrocket, diagnostics heavyweight GE Healthcare and Japanese-based Takeda are teaming up to develop new drugs to counter the trend.
The growing scourge of liver disease in the developed world has spurred a frenzied race among drug developers to ferret out new therapies, and Takeda, new to the field, has recruited the diagnostics experts at GE Healthcare to shepherd its early R&D efforts.
With former collaborator Astellas Pharma long since out the door, Aveo Oncology has found another partner willing to take a shot on the troubled tivozanib, signing a modest deal with Ophthotech to see how the cancer drug fares in eye diseases.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.
Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.
Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.